Search
Lobucavir
go.drugbank.com/drugs/DB12531InvestigationalLobucavir has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
Naveglitazar
go.drugbank.com/drugs/DB12662InvestigationalNaveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.
PHA-793887
go.drugbank.com/drugs/DB12686InvestigationalPHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.
CRA-028129
go.drugbank.com/drugs/DB05951ExperimentalCRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.
Dapivirine
go.drugbank.com/drugs/DB08639InvestigationalDapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.
Axelopran
go.drugbank.com/drugs/DB12013InvestigationalAxelopran has been used in trials studying the treatment of OIC and Opioid-induced Constipation.
Balapiravir
go.drugbank.com/drugs/DB12283InvestigationalBalapiravir has been used in trials studying the treatment of Dengue and Hepatitis C, Chronic.
J147
go.drugbank.com/drugs/DB13957Experimentalthat impacts many pathways implicated in the pathogenesis of diabetic neuropathy. … [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging
Synonyms: N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazideLecithin, soybean
go.drugbank.com/drugs/DB14161InvestigationalLecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. … The emulsifying and surfactant properties are useful in food additives and for forming organogels (gels).
AZD7442
go.drugbank.com/drugs/DB15787InvestigationalAZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]